603368 柳药集团
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入10,526,1142.19%20,926,27121,182,45420,811,90319,052,831
减:营业总成本10,091,0913.09%20,015,83120,166,80619,726,39318,126,741
    其中:营业成本9,427,7132.92%18,614,57618,774,82318,337,66516,860,778
               财务费用99,180-9.52%217,888235,205249,462220,168
               资产减值损失----(14,201)------
公允价值变动收益------------
投资收益1,107-46,469.66%(52)(95)(706)7,412
    其中:对联营企业和合营企业的投资收益(2)-5.84%248(132)(715)(189)
营业利润434,226-14.02%882,3851,003,5981,043,683890,061
利润总额425,387-14.76%869,9421,003,1361,043,381890,401
减:所得税费用54,027-10.92%149,405135,602136,777131,426
净利润371,360-15.29%720,536867,534906,604758,976
减:非控股权益2,189-75.96%11,07312,66257,01257,458
股东净利润369,171-14.00%709,464854,872849,592701,518

市场价值指针
每股收益 (元) *0.930-13.89%1.7902.2102.3501.940
每股派息 (元) *----0.6800.7510.6000.508
每股净资产 (元) *19.8394.06%19.32719.11017.84716.057
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容